HAS says OK to continue the reimbursement of Zykadia (ceritinib) for ALK + NSCLC

HAS gave a positive opinion to continue the reimbursement of Zykadia (ceritinib) for patients with ALK-positive non-small-cell lung cancer. The drug is reimbursed for patients who were previously treated with crizotinib.

Also read: Denmark Healthcare System

Crizotinib is the first product approved for ALK-positive NSCLC, which demonstrated the superiority over chemotherapy.

Alecensa (alectinib) had demonstrated superiority in progression-free survival and the risk of brain progression over crizotinib; it is the preferred treatment option for the first-line treatment of ALK+ lung cancer.

HAS has recommended Zyadia as a second-line treatment option after failure of first treatment (preferentially alectinib).

Zyadia received ASMR V considering the gain in progression-free survival versus chemotherapy. However, HAS believed that the trial result does not reflect the current treatment strategy.

The product has achieved SMR ‘Important.’


Please donate to support iPharmaCenter. Click on donate button in header to support us. Thank you

©2020 by ipharmaservices